Share
Australian Gynaecological Cancer Foundation Monthly Recurring Donation
The lifetime risk of a woman developing a gynae cancer is 1 in 20, so almost every Australian will have a close friend or relative affected. With only a 68% survival rate, a diagnosis of a gynae cancer comes with an unacceptably high mortality rate.
“There appears to be a relationship between levels of direct research investment and improvements in 5-year relative survival… cancers which receive larger amounts of direct funding to research projects… have shown greater improvements in 5-year relative survival.” (Cancer Council)
Is enough research being done?
A lot of research is being done, but much more could be done with more financial resources. Money raised by the AGCF will be used to fund research, both through the ANZGOG clinical trials, and through laboratory research into the various cancers.
Every five hours an Australian woman affected by a gynae cancer dies
30 years ago, breast cancer had a 5–year survial rate of 72% and gynae cancer had a 5-year survival rate of 59%. By 2015, the 5-year survival rate for breast cancer had increased to 90%, while the 5-year survival for gynae cancer was still only 68%. This means that the survival for gynae cancer is improving at only half the rate as breast cancer.
Well funded research has the ability to deliver very substantial improvements in survival. It’s that simple and every moment counts.
More than 5500 new cases are diagnosed each year in Australia. This is predicted to rise to 6000 new cases by 2020. These cancers represent 10% of all cancers in women, and cause 9% of cancer-related deaths in women.
Since the human genome project was completed in 2003, rapid progress has been made in cancer research, but progress has been slow for gynae cancers because comparatively little research money has been allocated to these cancers. By providing more charity research grant money, we will be able to attract more scientists to work in the field of gynae cancers.